Teva Pharmaceutical Industries Limited Receives European Marketing Authorization for ZOELY(TM) Oral Contraceptive

Published: Aug 02, 2011

JERUSALEM--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd (NASDAQ: TEVA) announced today that its new oral contraceptive, ZOELY™ (NOMAC/E2 –nomegestrol acetate 2.5 mg/17ß-estradiol 1.5 mg), has received a Marketing Authorization in the European Union (EU) for the prevention of pregnancy. This clears the way to allow the product to be launched in Europe by the end of 2011.

Back to news